Kodiak Sciences reported that its lead candidate, Zenkuda (tarcocimab tedromer), met its primary endpoint in the Phase 3 GLOW2 study for diabetic retinopathy. In the trial, 62.5 % of patients receiving Zenkuda achieved a ≥2‑step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at week 48, compared with only 3.3 % in the sham arm, yielding a highly significant p‑value of <0.0001. The safety profile was also favorable, with no cases of intra‑ocular inflammation, retinal vasculitis, or occlusive retinal vasculitis, and cataract incidence was low (2.3 % in the Zenkuda arm versus 1.6 % in sham).
The data support Kodiak’s strategy to file a 2026 Biologics License Application (BLA) for Zenkuda across multiple retinal indications. The study’s success validates the company’s antibody‑biopolymer conjugate (ABC) platform, which is designed to deliver durable efficacy while reducing injection frequency. A positive Phase 3 result also strengthens the company’s competitive positioning against established anti‑VEGF therapies in a $15 billion market, potentially opening a multi‑billion‑dollar opportunity if regulatory approval is obtained.
CEO Victor Perlroth said the results confirm that Zenkuda now has a multi‑indication BLA‑ready profile and that the company intends to accelerate its submission plans. Dr. Velazquez‑Martín noted that changes made to the study design likely contributed to the strong outcomes, even as the trial enrolled patients with more advanced disease.
In the same reporting period, Kodiak posted a Q4 2025 loss of $1.01 per share, which met analyst expectations. The company’s prior Q3 2025 loss of $1.16 per share had missed expectations, underscoring the ongoing cash burn typical of a pre‑commercial biotech. Kodiak remains a zero‑revenue company, with its financials driven primarily by R&D and regulatory milestones rather than product sales.
Beyond Zenkuda, Kodiak is advancing other pipeline candidates, including KSI‑501 (targeting VEGF and IL‑6) and KSI‑101, with topline data expected for the DAYBREAK study in late 2026. The company’s focus on retinal indications positions it to capture a share of the anti‑VEGF market, while the ABC platform could differentiate its products through improved durability and reduced injection burden.
The announcement was well received by investors, reflecting confidence in the data and the company’s strategic trajectory toward regulatory approval and commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.